JP2022512326A5 - - Google Patents
Info
- Publication number
- JP2022512326A5 JP2022512326A5 JP2021532126A JP2021532126A JP2022512326A5 JP 2022512326 A5 JP2022512326 A5 JP 2022512326A5 JP 2021532126 A JP2021532126 A JP 2021532126A JP 2021532126 A JP2021532126 A JP 2021532126A JP 2022512326 A5 JP2022512326 A5 JP 2022512326A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- antigen
- tcr
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776012P | 2018-12-06 | 2018-12-06 | |
| US62/776,012 | 2018-12-06 | ||
| PCT/US2019/064757 WO2020118094A1 (en) | 2018-12-06 | 2019-12-05 | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512326A JP2022512326A (ja) | 2022-02-03 |
| JP2022512326A5 true JP2022512326A5 (https=) | 2022-12-09 |
| JP7571021B2 JP7571021B2 (ja) | 2024-10-22 |
Family
ID=70974859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532126A Active JP7571021B2 (ja) | 2018-12-06 | 2019-12-05 | 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210369776A1 (https=) |
| JP (1) | JP7571021B2 (https=) |
| KR (1) | KR20210112310A (https=) |
| CN (1) | CN113226335B (https=) |
| SG (1) | SG11202105975SA (https=) |
| TW (1) | TW202039545A (https=) |
| WO (1) | WO2020118094A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019301070B2 (en) | 2018-07-09 | 2025-09-11 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| CN111718409B (zh) * | 2020-06-17 | 2021-03-02 | 深圳豪石生物科技有限公司 | 一种t细胞受体及其应用 |
| WO2022011256A1 (en) * | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| CN112940108B (zh) * | 2021-03-19 | 2022-10-14 | 河南省肿瘤医院 | 识别ebv抗原的t细胞受体以及该t细胞受体的应用 |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| CN116179493A (zh) * | 2021-09-29 | 2023-05-30 | 成都美杰赛尔生物科技有限公司 | 敲除两种免疫检测点基因的免疫细胞及其制备方法与应用 |
| WO2024054863A1 (en) * | 2022-09-06 | 2024-03-14 | Board Of Regents, The University Of Texas System | T-cell receptor that targets egfr mutation and methods of using the same |
| EP4665363A1 (en) * | 2023-02-17 | 2025-12-24 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of preventing t cell exhaustion |
| CN119390814B (zh) * | 2023-10-26 | 2025-06-27 | 上海市第一人民医院 | 一种t细胞受体及其制备方法和用途 |
| CN119978143B (zh) * | 2025-01-26 | 2025-10-21 | 湖南大学 | 一种基于synNotch的工程化巨噬细胞及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060002941A1 (en) * | 2004-01-23 | 2006-01-05 | Vievax Corp. | Compositions comprising immune response altering agents and methods of use |
| HRP20171164T1 (hr) * | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| BR112016014952A2 (pt) * | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3286211A1 (en) * | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CA2997551A1 (en) * | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| US20190048085A1 (en) * | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| EP3432924A1 (en) * | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| US12060394B2 (en) * | 2016-04-28 | 2024-08-13 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
| AU2018231405B2 (en) * | 2017-03-07 | 2024-02-08 | Universität Basel | MR1 restricted T cell receptors for cancer immunotherapy |
| CN110536700A (zh) * | 2017-04-19 | 2019-12-03 | 南加利福尼亚大学 | 用于治疗癌症的组合物和方法 |
| AU2018266103B2 (en) * | 2017-05-09 | 2024-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies |
-
2019
- 2019-12-05 CN CN201980081064.XA patent/CN113226335B/zh active Active
- 2019-12-05 KR KR1020217019705A patent/KR20210112310A/ko active Pending
- 2019-12-05 WO PCT/US2019/064757 patent/WO2020118094A1/en not_active Ceased
- 2019-12-05 JP JP2021532126A patent/JP7571021B2/ja active Active
- 2019-12-05 US US17/311,114 patent/US20210369776A1/en not_active Abandoned
- 2019-12-05 SG SG11202105975SA patent/SG11202105975SA/en unknown
- 2019-12-06 TW TW108144761A patent/TW202039545A/zh unknown
-
2024
- 2024-12-04 US US18/968,399 patent/US20250243293A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512326A5 (https=) | ||
| JP7744479B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 | |
| JP2020096630A5 (https=) | ||
| JP2021520198A5 (https=) | ||
| CN103483452B (zh) | 双信号独立的嵌合抗原受体及其用途 | |
| CN109651511B (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
| JP2020537515A5 (https=) | ||
| CN112480239B (zh) | 人乳头瘤病毒特异性t细胞受体及其抗肿瘤用途 | |
| JP2025511151A (ja) | 抗ｃｄ７ナノボディおよびその派生物ならびに腫瘍治療におけるその使用 | |
| CN106046162B (zh) | 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用 | |
| JP2018535668A5 (https=) | ||
| JP7572465B2 (ja) | Ｔ細胞抗原受容体、その多量体複合体、その調製方法及び使用 | |
| CN111925451B (zh) | 一种靶向bcma的嵌合抗原受体(car)及其应用 | |
| US20230357355A1 (en) | Cspg4-targeting humanized chimeric antigen receptor, immune effector cell expressing chimeric antigen receptor, and applications thereof | |
| JP2023518578A5 (https=) | ||
| EP3733695A1 (en) | Dual-activating costimulatory molecule receptor and use thereof | |
| CN113004415B (zh) | 靶向her2和4-1bb的双特异性抗体及其应用 | |
| CN115466331B (zh) | 靶向bcma的嵌合抗原受体及其应用 | |
| TW202142561A (zh) | 抗ｈｐｖ ｔ細胞受體和工程化細胞 | |
| JP2024518680A (ja) | Ｔ細胞調節ポリペプチド及びその使用方法 | |
| CN112996909A (zh) | 表达pd-1结合蛋白的溶瘤病毒及其应用 | |
| CN113272016A (zh) | 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法 | |
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| CN111944053A (zh) | 抗bcma的car及其表达载体和应用 | |
| CN111850014A (zh) | 一种细胞因子增效的嵌合抗原受体及其应用 |